Jeffrey A How (Jeffrey How)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Endometrial Cancer

Skeletal Muscle

Top Venues

Nature reviews. Clinical oncology

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey A How, Amir A Jazaeri, Shannon Neville Westin, Barrett C Lawson, Ann H Klopp, Pamela T Soliman, Karen H Lu
Translating biological insights into improved management of endometrial cancer. Nature reviews. Clinical oncology (2024)
Jeffrey A How, Amir A Jazaeri, Siqing Fu, Jordi Rodon Ahnert, Jing Gong, Bettzy Stephen, Hanna Rafaela Ferreira Dalla Pria, Priya Bhosale, Amber Johnson, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers 14 (15) (2022)
Jeffrey A How, Amir A Jazaeri, Pamela T Soliman, Nicole D Fleming, Jing Gong, Sarina A Piha-Paul, Filip Janku, Bettzy Stephen, Aung Naing
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Scientific reports 11 (1) (2021)
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms, Karen H Lu, Melinda S Yates
Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers 13 (5) (2021)
Jeffrey A How, Amir Jazaeri, Shannon N Westin, Anil K Sood, Lois M Ramondetta, Mingxuan Xu, Abdulrahman Abonofal, Daniel D Karp, Vivek Subbiah, Bettzy Stephen, Jordi A Rodon, Fei Yang, Aung Naing
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Investigational new drugs 39 (3) (2021)
Sena Turkdogan, Gabriel Schnitman, Tianci Wang, Raphael Gotlieb, Jeffrey A How, Walter Henri Gotlieb
Development of a Digital Patient Education Tool for Patients With Cancer During the COVID-19 Pandemic. JMIR cancer 7 (2) (2021)